32 citations,
June 2017 in “Journal of Pharmaceutical Sciences” Chitosan-coated nanoparticles improve skin delivery of hair loss treatments with fewer side effects.
10 citations,
May 2010 in “Analytica Chimica Acta” New tests detect finasteride and dutasteride in urine quickly and easily.
90 citations,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
21 citations,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
6 citations,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
1 citations,
January 2015 in “Hair therapy & transplantation” New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
49 citations,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
29 citations,
April 2019 in “BMJ. British medical journal” Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
27 citations,
October 2001 in “Journal of Medicinal Chemistry” Researchers found new potential but less potent rat enzyme inhibitors using a 3D model.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
10 citations,
August 2020 in “International Journal of Andrology” 5α-reductase inhibitors like finasteride may not be effective or safe for transgender individuals, and more research is needed.
3 citations,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
147 citations,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
54 citations,
May 2018 in “International journal of risk & safety in medicine” Antidepressants, 5α-reductase inhibitors, and isotretinoin can cause long-lasting sexual dysfunction.
45 citations,
February 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
28 citations,
May 1986 in “Clinics in endocrinology and metabolism” New compounds may soon be tested to treat excessive hair growth in women.
26 citations,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
20 citations,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
17 citations,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
16 citations,
August 2014 in “Archives of Pharmacal Research” Special nanoparticles increased skin absorption of hair loss treatments with fewer side effects.
12 citations,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
3 citations,
October 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
2 citations,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
2 citations,
April 2017 in “European Urology” Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” Finasteride improves hair growth in men with androgenetic alopecia.
66 citations,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
66 citations,
June 2013 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
50 citations,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
17 citations,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.